Earliest use of initial prophylactic dose of magnesium sulphate (MgSO4) in severe pre-eclampsia to improve maternal and perinatal outcome, in a rural medical college, WB, India

Suresh Chandra Mondal, Sandip Lahiri, Sudip Ranjan Paul

Abstract


Background: Eclampsia is one of the high risk obstetric complication throughout the world. Till today, eclampsia is one of the important cause of maternal mortality in our country. However the administration of magnesium sulphate (MgSO4) has changed the scenario significantly.  

Methods: The study includes 100 patients with severe pre-eclampsia admitted Malda medical college hospital, from 1st June 2013 to 30th April 2014. This study compares the maternal fatal outcome between two groups of patients with severe pre-eclampsia (BP ≥160/110 mm. proteinuria 2 gm/24 hours. or ≥2 + dipstick.). The first group of patients were admitted in this institution after being referred from primary and secondary health care facilities, after getting initial prophylactic dose of magnesium sulphate (MgSO4) (Group A). The second group (Group B) includes those patients who were admitted without getting any prophylactic dose of magnesium sulphate (MgSO4) from outside.

Results: Patients were included, in group A, eclampsia and maternal mortality were nil. Where as in group B eight (8) patients (16%) had eclampsia and 4 patents (8%) expired.

Conclusions: Initial dose prophylactic magnesium sulphate (MgSO4) the earliest, can prevent both maternal perinatal maternal mortality. So, prophylactic magnesium sulphate (MgSO4) must be started at the first point of contact by trained health providers.


Keywords


Pre-eclampsia, Magnesium sulphate, Prophylactic dose

Full Text:

PDF

References


The Magpie Trial. Collaboration Group. Do women with preeclampsia and their babies benefit from magnesium sulphate? The magpie trial: a randomized placebo controlled trial. Lancet. 2002;359:1877-90.

The National Institute for Clinical Excellence, The Scottish Executive Health Department. The Department of Health, Social Services and Public Safety, Northern Ireland. Why mothers die 1997-1999: the fifth report of UK confidential enquiries into maternal deaths. In: NSH, eds. NSH Report. London; RCOG Press, 2001: 1-4.

Sibai BM. Magnesium sulphate prophylaxis in preeclampsia: lessons learnt from recent trials. Am J Obstet Gynecol. 2004;190:1520-6.

Sibai BM. Magnesium sulphate is the ideal anticonvulsant in pre-eclampsia. Am J Obstet Gynecol. 1990;162:1141-5.

Talatnaz, Lubna Hasan, Mehrunnisa. Eclampsia: management and outcome with magnesium sulpahate as the anticonvulsant. J Coll Physicians Surg Pak 2005;15:624-7.

Moodley J, Moodey VV. Prophylactic anticonvulsant therapy in hypertensive crises of pregnancy: the need for a large randomized trial. Hyper Pregnancy. 1994;13:245-52.

Coetzee E, Dommisse J, Anthony J. A randomized control trial of intravenous magnesium sulphate versus placebo in the management of women with severe pre-eclampsia. Br J Obstet Gynaecol. 1998;105:300-3.

Odendaal HJ, Hall DR. Is magnesium sulphate prophylaxis necessary in pre-eclampsia? Outcome of infants delivered between 24 and 28 weeks’ gestation in women with severe preeclampsia. J Maternal Fetal Invest. 1996;6:14-8.

Hiett AK, Brown HL, Britton KA. Outcome of infants delivered between 24 and 28 weeks’ gestation in women with severe preeclampsia. Fetal Med. 2001;10:301-4.

Hall DR, Odendal HJ, Smith MI. Prophylactic administration of magnesium sulphate is indicated prior to labour? Br J Obstet Gynecol. 2000;107:903-8.

Pritchard JA, Cunningham FG, Pritchard SA. The Parkland Memorial hospital protocol for treatment of eclampsia: evaluation of 245 cases. Am J Obstet Gynecol. 1984;148:951-63.

Khan KS, Wojdyla D, Say L, Gulmezoglu AM, Van Look PFA. WHO analysis of causes of maternal death: a systematic review. Lancet. 2006;367:1066-74.

WHO International Collaborative Study of Hypertensive Disorders of Pregnancy. Geographic variation in the incidence of hypertension in pregnancy. Am J Obstet Gynecol. 1998;158:80-3.

Baha Sibai, Brianet AL. Aggressive versus expectant management of severe pre-eclampsia at 28-32 weeks gestation: a randomized control trial. Am J Obstet Gynecol. 1994;171:818.

Belfort MA, Anthony J, Saade GR, Allen JC. A comparison of magnesium sulphate and nimodipine for prevention of eclampsia. N Engl Med. 2003;348:304-11.

Zuspan FP, Ward MC. Improved fetal salvage in eclampsia. Obstet Gynecol. 1965;26:893-7.

Begum MR, Begum A, Quadir E. Loading dose versus standard regime of magnesium sulphate in the management of eclampsia: a randomized trial: J Obstet Gynaecol Res. 2002;28:154-9.

Noor S, Halimi M, Ruby N, Gull F, Akbar N. Magnesium sulphate in the prophylaxis and treatment of eclampsia. J Ayub Med Coll Abbottabad. 2004;16:50-4.

Sibai BM. Eclampsia. VI. Maternal-perinatal outcome in 254 consecutive cases. Am J Obstet Gynecol. 1990;163:1049-55.

Pritchard JA, Cunningham FG, Pritchard SA. The Parkland Memorial hospital protocol for treatment of eclampsia: evaluation of 245 cases. Am J Obstet Gynecol. 1984;148:951-63.

Usta IM, Sibai BM. Emergent management of puerperal eclampsia. Obstet Gynecol Clin N Am. 1995;22:315-33.

Lu JF, Nightingle CH. Magnesium sulphate in eclampsia and pre-eclampsia. Clin Pharmacokinet. 2000;38:305-14.

Gofton EN, Capewell V, Natale R, Gratton RJ. Obstetrical intervention rates and maternal and neonatal outcomes of women with gestational hypertension. Am J Obstet Gynecol. 2001;185:798-803.

Magpie Trial Follow-Up Study Management Group. The Magpie trial follow up study: outcome after discharge from hospital for women and children recruited to a trial comparing magnesiumsulphate with placebo for pre-eclampsia. BMC Pregnancy Childbirth 2004;4:5.

Magpie Trial Follow Up Study Collaborative Group. The Magpie trial: a randomized trial comparing magnesium sulphate with placebo for pre-eclampsia. Outcome for women at 2 years. BJOG. 2007;114:300-9.